The LD/CD line of product candidates includes:
• ND0612L: for moderate Parkinson’s disease patients
• ND0612H: for severe Parkinson’s disease patients
In addition to the LD/CD line of product candidates, NeuroDerm is also developing a novel formulation of continuous apomorphine therapy. Continuous apomorphine therapy is aimed at Parkinson’s disease patients who do not respond well or cannot be treated with LD/CD. The current marketed apomorphine product suffers from detrimental side effects that prevent its more widespread use. ND0701 is NeuroDerm’s next-generation alternative to the currently available continuous apomorphine therapy.
We are also developing ND0801, a product candidate for patients suffering from cognitive disorders associated with central nervous system diseases. These diseases include Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer’s disease, Parkinson’s disease and schizophrenia. This line of products will be based on a combination of reformulated approved drugs and will allow for continuous administration via transdermal patches.